Gene Expression Following Ultherapy® Treatment

Inclusion Criteria: * Male or female, age 45 to 70 years. * Subject in good health. * Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period. * Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. * Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the Screening Visit and be willing and able to use an acceptable method of birth control during the study. * Absence of physical or psychological conditions unacceptable to the investigator. * Willingness to refrain from use of aspirin, Ibuprofen, Naproxen or any other Non-Steroidal Anti-Inflammatory Drug (NSAID) prior to study treatment and chronic use during the entire post-treatment study period. * Willingness and ability to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization prior to performance of any study-related procedure. Exclusion Criteria: * Presence of an active systemic or local skin disease that may affect wound healing. * Severe solar elastosis. * Significant scarring in the area(s) to be treated that would interfere with assessing results. * Open wounds or lesions in the area(s) to be treated. * Severe or cystic acne on the area(s) to be treated. * Active implants (e.g., pacemakers or defibrillators), or metallic implants in the treatment areas (dental implants not included.) * Inability to understand the protocol or to give informed consent. * Microdermabrasion, or prescription level glycolic acid treatment to the treatment area(s) within four weeks prior to study participation or during the study. * Excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area(s) to be treated. * BMI equal to or greater than 30. * History of chronic drug or alcohol abuse. * History of autoimmune disease. * Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device. * Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability. * Concurrent enrollment in any study involving the use of investigational devices or drugs. * Current smoker or history of smoking in the last five years. * Current user of any nicotine-containing products, e.g., e-cigarettes, Nicorette gum, nicotine patches, etc. * History of the following cosmetic treatments in the area(s) to be treated: 1. Skin tightening procedure within the past year; 2. Injectable filler of any type within the past: i. 12 months for Hyaluronic acid fillers (e.g. Restylane) ii. 12 months for Ca Hydroxyapatite fillers (e.g. Radiesse) iii. 24 months for Long-lasting Hyaluronic acid (Juvéderm Voluma) and Poly-L-Lactic acid fillers (e.g. Sculptra) iv. Ever for permanent fillers (e.g. Silicone, ArteFill) c. Neurotoxins within the past three months; d. Ablative resurfacing laser treatment within the past six months; e. Nonablative, rejuvenative laser or light treatment within the past six months; f. Surgical dermabrasion or deep facial peels; or g. Facelifts within the past year. * History of using the following prescription medications: 1. Accutane or other systemic retinoids within the past six months; 2. Topical Retinoids within the past two weeks; 3. Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix); 4. Psychiatric drugs that in the investigators opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.